SAB Biotherapeutics (SABS) Short Interest Ratio & Short Volume → Investors Alert: The Next Big Thing in Weight Loss (From Behind the Markets) (Ad) Free SABS Stock Alerts $4.03 +0.01 (+0.25%) (As of 05/3/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media SAB Biotherapeutics Short Interest DataCurrent Short Volume25,600 sharesPrevious Short Volume28,900 sharesChange Vs. Previous Month-11.42%Dollar Volume Sold Short$111,616.00Short Interest Ratio / Days to Cover1.8Last Record DateApril 15, 2024Outstanding Shares9,230,000 sharesFloat Size7,480,000 sharesShort Percent of Float0.34%Today's Trading Volume2,533 sharesAverage Trading Volume2,795 sharesToday's Volume Vs. Average91% Short Selling SAB Biotherapeutics ? Sign up to receive the latest short interest report for SAB Biotherapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatSABS Short Interest Over TimeSABS Days to Cover Over TimeSABS Percentage of Float Shorted Over Time Ad Behind the MarketsInvestors Alert: The Next Big Thing in Weight LossUBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Pharma's biggest blockbuster yet." Bank of America predicts it will be the world's first "$100 billion dollar a year drug." And Morgan Stanley predicts 250 million prescriptions will be written each year. Get the name of the stock here >>> SAB Biotherapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/202425,600 shares $111,616.00 -11.4%0.3%1.8 $4.36 3/31/202428,900 shares $131,206.00 +38.3%0.4%1.7 $4.54 3/15/202420,900 shares $115,368.00 -15.0%0.3%1.1 $5.52 2/29/202424,600 shares $109,716.00 -37.1%0.3%1.5 $4.46 2/15/202439,100 shares $217,005.00 +17.8%0.5%2.9 $5.55 1/31/202433,200 shares $199,200.00 +90.8%0.4%2.8 $6.00 Get the Latest News and Ratings for SABS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/202417,400 shares $104,052.00 -2.8%0.2%1.5 $5.98 12/31/202317,900 shares $12,306.25 -91.4%N/A2.1 $0.69 12/15/2023207,600 shares $153,291.84 -11.2%0.3%3 $0.74 11/30/2023233,700 shares $227,156.40 +1.7%0.7%3.8 $0.97 11/15/2023229,800 shares $209,118.00 -12.1%0.6%4.4 $0.91 10/31/2023261,400 shares $261,373.86 -2.2%0.7%5.2 $1.00 10/15/2023267,200 shares $187,574.40 -2.8%0.7%6.4 $0.70 9/30/2023274,900 shares $173,187.00 -10.3%0.7%7.4 $0.63 9/15/2023306,500 shares $199,225.00 -17.5%0.8%8.5 $0.65 8/31/2023371,600 shares $267,552.00 +8.8%1.0%7 $0.72 8/15/2023341,500 shares $269,785.00 -12.3%0.9%5.9 $0.79 7/31/2023389,300 shares $315,333.00 -12.4%1.1%4.7 $0.81 7/15/2023444,400 shares $385,472.56 -4.1%1.3%1.6 $0.87 6/30/2023463,200 shares $384,456.00 +27.2%1.3%0.3 $0.83 6/15/2023364,300 shares $329,691.50 -14.9%1.0%0.3 $0.91 5/31/2023428,100 shares $381,009.00 -35.7%1.2%0.3 $0.89 5/15/2023665,400 shares $585,552.00 +28.3%1.9%0.5 $0.88 4/30/2023518,600 shares $465,858.38 +287.6%1.5%0.4 $0.90 4/15/2023133,800 shares $97,071.90 -3.2%0.4%0.1 $0.73 3/31/2023138,200 shares $60,808.00 -30.1%0.4%3.4 $0.44 3/15/2023197,800 shares $100,878.00 +17.5%0.6%4.3 $0.51 2/28/2023168,300 shares $109,395.00 +14.1%0.5%3.2 $0.65 2/15/2023147,500 shares $97,792.50 -2.8%0.5%2.7 $0.66 1/31/2023151,700 shares $103,064.98 +3.1%0.5%2.3 $0.68 1/15/2023147,100 shares $109,427.69 -14.4%0.5%2.1 $0.74 12/30/2022171,800 shares $101,344.82 -14.4%0.6%2.5 $0.59 12/15/2022200,700 shares $184,684.14 -6.1%0.7%2.8 $0.92 11/30/2022213,700 shares $230,796.00 -11.1%0.8%2.8 $1.08 11/15/2022240,300 shares $254,718.00 +8.2%0.9%3.1 $1.06 10/31/2022222,200 shares $199,980.00 -15.3%0.8%3.1 $0.90 10/15/2022262,400 shares $208,634.24 +7.7%0.9%3.8 $0.80 9/30/2022243,600 shares $170,763.60 +22.8%0.9%3.6 $0.70 9/15/2022198,300 shares $164,589.00 -22.1%0.7%3.6 $0.83 8/31/2022254,600 shares $178,245.46 +6.3%1.0%4.5 $0.70Automatic Income (from home) (Ad)For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year. Just click here now to watch my presentation for free. SABS Short Interest - Frequently Asked Questions What is SAB Biotherapeutics' current short interest? Short interest is the volume of SAB Biotherapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, traders have sold 25,600 shares of SABS short. 0.34% of SAB Biotherapeutics' shares are currently sold short. Learn More on SAB Biotherapeutics' current short interest. What is a good short interest ratio for SAB Biotherapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. SABS shares currently have a short interest ratio of 2.0. Learn More on SAB Biotherapeutics's short interest ratio. What is a good short interest percentage for SAB Biotherapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.34% of SAB Biotherapeutics' floating shares are currently sold short. Is SAB Biotherapeutics' short interest increasing or decreasing? SAB Biotherapeutics saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 25,600 shares, a decrease of 11.4% from the previous total of 28,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is SAB Biotherapeutics' float size? SAB Biotherapeutics currently has issued a total of 9,230,000 shares. Some of SAB Biotherapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. SAB Biotherapeutics currently has a public float of 7,480,000 shares. How does SAB Biotherapeutics' short interest compare to its competitors? 0.34% of SAB Biotherapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to SAB Biotherapeutics: Curis, Inc. (1.01%), Sangamo Therapeutics, Inc. (6.39%), Estrella Immunopharma, Inc. (0.05%), Dyadic International, Inc. (0.92%), Cyclo Therapeutics, Inc. (0.47%), OKYO Pharma Limited (0.50%), Surrozen, Inc. (1.89%), MiNK Therapeutics, Inc. (0.49%), Protara Therapeutics, Inc. (4.35%), Quince Therapeutics, Inc. (6.21%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short SAB Biotherapeutics stock? Short selling SABS is an investing strategy that aims to generate trading profit from SAB Biotherapeutics as its price is falling. SABS shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against SAB Biotherapeutics? A short squeeze for SAB Biotherapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of SABS, which in turn drives the price of the stock up even further. How often is SAB Biotherapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SABS, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Curis Short Interest Data Sangamo Therapeutics Short Interest Data Estrella Immunopharma Short Interest Data Dyadic International Short Interest Data Cyclo Therapeutics Short Interest Data OKYO Pharma Short Interest Data Surrozen Short Interest Data MiNK Therapeutics Short Interest Data Protara Therapeutics Short Interest Data Quince Therapeutics Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:SABS) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCInvestors Alert: The Next Big Thing in Weight LossBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe asset beating inflation by 4xColonial MetalsHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceWarren Buffet Stockpiling Gold?Reagan Gold Group